Literature DB >> 22684070

Crystallization and preliminary X-ray analysis of the C-terminal domain of CCM2, part of a novel adaptor protein involved in cerebral cavernous malformations.

Xiaoyan Wang1, Jingjin Ding, Dacheng Wang.   

Abstract

Cerebral cavernous malformation 2 (CCM2) is a novel two-domain adaptor protein which participates in multiple cellular signalling pathways. Loss-of-function mutations in the gene encoding CCM2 are the cause of common human vascular lesions called cerebral cavernous malformations. Here, the purification, crystallization and preliminary X-ray crystallographic studies of the C-terminal domain of CCM2 (CCM2-Ct) are reported. Diffraction data were collected from native and selenomethionine-substituted crystals of CCM2-Ct to resolutions of 2.9 and 2.7 Å, respectively. Both crystals belonged to space group I4(1)22 with similar unit-cell parameters. The native crystals had unit-cell parameters a = b = 113.29, c = 101.62 Å.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684070      PMCID: PMC3370910          DOI: 10.1107/S1744309112016181

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  9 in total

1.  Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock.

Authors:  Mark T Uhlik; Amy N Abell; Nancy L Johnson; Weiyong Sun; Bruce D Cuevas; Katherine E Lobel-Rice; Eric A Horne; Mark L Dell'Acqua; Gary L Johnson
Journal:  Nat Cell Biol       Date:  2003-11-23       Impact factor: 28.824

Review 2.  Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction.

Authors:  Eva Faurobert; Corinne Albiges-Rizo
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

Review 3.  Cerebral cavernous malformation: new molecular and clinical insights.

Authors:  N Revencu; M Vikkula
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

4.  Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis.

Authors:  Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

5.  CCM2 mediates death signaling by the TrkA receptor tyrosine kinase.

Authors:  Liraz Harel; Barbara Costa; Marianna Tcherpakov; Marc Zapatka; Andre Oberthuer; Loen M Hansford; Milijana Vojvodic; Zehava Levy; Zhe-Yu Chen; Francis S Lee; Smadar Avigad; Isaac Yaniv; Leming Shi; Roland Eils; Matthias Fischer; Benedikt Brors; David R Kaplan; Mike Fainzilber
Journal:  Neuron       Date:  2009-09-10       Impact factor: 17.173

6.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

7.  A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells.

Authors:  Axel Pagenstecher; Sonja Stahl; Ulrich Sure; Ute Felbor
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

8.  The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases.

Authors:  Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

9.  Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway.

Authors:  Benjamin Kleaveland; Xiangjian Zheng; Jian J Liu; Yannick Blum; Jennifer J Tung; Zhiying Zou; Shawn M Sweeney; Mei Chen; Lili Guo; Min-min Lu; Diane Zhou; Jan Kitajewski; Markus Affolter; Mark H Ginsberg; Mark L Kahn
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.